Avalo Therapeutics
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 7.0m | 5.0m | 18.0m | 1.9m | 1.2m | 1.0m | 1.0m |
% growth | (59 %) | (29 %) | 260 % | (89 %) | (38 %) | (17 %) | - |
Profit | (64.0m) | (84.0m) | (42.0m) | (31.5m) | (46.7m) | (51.8m) | (57.0m) |
% profit margin | (914 %) | (1680 %) | (233 %) | (1639 %) | (3892 %) | (5180 %) | (5700 %) |
EV / revenue | 601.7x | 38.2x | 2.6x | 3.8x | 56.5x | 67.8x | 67.8x |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $22.1m | Series A | |
N/A | $6.8m | Series A | |
$32.0m | Series B | ||
N/A | N/A | IPO | |
$1.0m | Grant | ||
N/A | $5.0m | Post IPO Equity | |
N/A | $36.4m | Post IPO Equity | |
$10.0m | Post IPO Debt | ||
* | N/A | $15.0m | Post IPO Equity |
* | $185m | Private Placement VC | |
Total Funding | AUD382m |
Related Content
Recent News about Avalo Therapeutics
EditCerecor Inc. is a biopharmaceutical company focused on developing innovative therapies for rare pediatric and orphan diseases. The company operates in the healthcare and biotechnology sectors, targeting unmet medical needs with a robust pipeline of forward-thinking ideas. Cerecor serves patients who suffer from rare conditions, often with limited treatment options, and aims to improve their quality of life through advanced scientific research and clinical trials. The business model revolves around the discovery, development, and commercialization of novel therapeutic solutions. Cerecor generates revenue through public offerings, strategic partnerships, and the eventual commercialization of its drug candidates. The company is listed on the Nasdaq under the ticker symbol CERC and actively engages in investor relations to secure funding for its ambitious projects.
Keywords: biopharmaceutical, rare diseases, pediatric, orphan diseases, innovative therapies, clinical trials, Nasdaq, healthcare, biotechnology, drug development.